{"nctId":"NCT04172831","briefTitle":"A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia","startDateStruct":{"date":"2019-12-09","type":"ACTUAL"},"conditions":["Fibromyalgia"],"count":503,"armGroups":[{"label":"TNX-102 SL Tablets, 5.6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TNX-102 SL"]},{"label":"Placebo SL Tablet","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo SL Tablet"]}],"interventions":[{"name":"TNX-102 SL","otherNames":["Low dose cyclobenzaprine sublingual tablets"]},{"name":"Placebo SL Tablet","otherNames":["Placebo sublingual tablets"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient is male or female 18 to 65 years of age, inclusive.\n* The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)\n* The in-clinic 7-day recall NRS average daily pain intensity score at Screening Visit within protocol specified range.\n\nExclusion Criteria:\n\n* History of or evidence for a diagnosis of borderline personality disorder (BPD).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.","description":"Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":null},{"groupId":"OG001","value":"-1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of \"Very Much Improved\" or \"Much Improved\"","description":"The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score","description":"The FIQ-R is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.4","spread":null},{"groupId":"OG001","value":"-14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the FIQR Function Domain Score","description":"The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":null},{"groupId":"OG001","value":"-9.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance","description":"The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.5","spread":null},{"groupId":"OG001","value":"-6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the PROMIS Score for Fatigue","description":"The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":null},{"groupId":"OG001","value":"-6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality","description":"Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null},{"groupId":"OG001","value":"-1.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":248},"commonTop":["Hypoaesthesia oral","Paraesthesia oral","Dysguesia"]}}}